格菲妥单抗治疗弥漫大B细胞淋巴瘤临床用药指导原则(2024年版)
Guidelines for clinical application of glofitamab in diffuse large B-cell lymphoma(2024 version)
中国临床肿瘤学会(CSCO)淋巴瘤专家委员会 马军1
作者信息
- 1. 哈尔滨血液病肿瘤研究所,哈尔滨150010
- 折叠
摘要
格菲妥单抗是一种2∶1结构、靶向CD20×CD3的新型双特异性抗体,单药或联合其他药物治疗复发或难治弥漫大B细胞淋巴瘤(DLBCL)可获得持续的缓解,并降低疾病进展或死亡风险,患者显著获益.格菲妥单抗是首个在全球范围内被批准用于DLBCL的双特异性抗体,在我国也新近获批用于治疗既往接受过至少二线系统性治疗的复发或难治DLBCL.专家组结合国内外相关研究和临床实践,制定了格菲妥单抗治疗DLBCL的临床用药指导原则,旨在为我国临床医师规范、合理用药提供参考.
Abstract
Glofitamab is a novel CD20×CD3 targeted bispecific antibody with a 2∶1 molecular format,which can be used as a monotherapy and in combination with other agents for the treatment of relapsed or refractory diffuse large B-cell lymphoma(DLBCL)to induce durable responses and reduce the risk of disease progression or death,as well as bring significant clinical benefit for patients.Glofitamab is the first bispecific antibody approved worldwide for the treatment of DLBCL.It has also recently been approved in China for the treatment of relapsed or refractory DLBCL that has received at least two prior lines of systemic therapy.By referring to relevant domestic and international researches and combining with clinical practice,the members of the expert group formulated the guiding principles for the treatment of DLBCL with glofitamab,in order to provide references for Chinese clinicians to standardize and rationalize drug usage.
关键词
淋巴瘤,大B细胞,弥漫性/格菲妥单抗/双特异性抗体Key words
Lymphoma,large B-cell,diffuse/Glofitamab/Bispecific antibody引用本文复制引用
出版年
2024
NETL
NSTL
万方数据